News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nymox Pharmaceutical (NYMX) Reports New Results On Favorable Side Effect Profile Of NX-1207 Treatment


5/21/2014 9:13:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HASBROUCK HEIGHTS, N.J., May 21, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report new positive data confirming the advantageous side effect profile of the Company's lead compound NX-1207. Results from the Brief Male Sexual Function Questionnaire (BMSF) in the Company's recently completed NX03-0040 trial of NX-1207 2.5 mg and 15 mg for the treatment of low grade localized prostate cancer indicate that targeted treatment with NX-1207 at either dose had no significant effect on reported sexual function score post-treatment.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES